Tuesday, September 27, 2016 3:28:47 PM
I also believe the relationship and/or benefit relative to the opioid issue is seriously overstated, but that's another discussion.....
Essentially, can BIEL manage enough dilution to remain in business until a major trigger event happens, barring a negative SEC action, and then build a profitable operating model without further need for share devaluation? Seems to be the crux of it, really. That places the case back on the FDA approval/non-approval. I don't really have an opinion on that debate, except to say the surrounding euphoria seems excessive, given the length of time BIEL has been fighting this battle. The SEC docs don't paint a pretty picture, but again I won't speculate on the outcome.
FDA or not - BIEL, with all these outside USA markets, will need to get that profitable operating model in place.....
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM